BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 17628029)

  • 1. Lentiviral vectors that carry anti-HIV shRNAs: problems and solutions.
    ter Brake O; Berkhout B
    J Gene Med; 2007 Sep; 9(9):743-50. PubMed ID: 17628029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.
    Ni Y; Sun S; Oparaocha I; Humeau L; Davis B; Cohen R; Binder G; Chang YN; Slepushkin V; Dropulic B
    J Gene Med; 2005 Jun; 7(6):818-34. PubMed ID: 15693055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1.
    Chang LJ; Liu X; He J
    Gene Ther; 2005 Jul; 12(14):1133-44. PubMed ID: 15750613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Production of lentiviral vectors by transient expression of minimal packaging genes from recombinant adenoviruses.
    Kuate S; Stefanou D; Hoffmann D; Wildner O; Uberla K
    J Gene Med; 2004 Nov; 6(11):1197-205. PubMed ID: 15459964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a novel trans-lentiviral vector that affords predictable safety.
    Wu X; Wakefield JK; Liu H; Xiao H; Kralovics R; Prchal JT; Kappes JC
    Mol Ther; 2000 Jul; 2(1):47-55. PubMed ID: 10899827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods.
    Sastry L; Johnson T; Hobson MJ; Smucker B; Cornetta K
    Gene Ther; 2002 Sep; 9(17):1155-62. PubMed ID: 12170379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors.
    Sparacio S; Pfeiffer T; Schaal H; Bosch V
    Mol Ther; 2001 Apr; 3(4):602-12. PubMed ID: 11319923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors.
    Wagner R; Graf M; Bieler K; Wolf H; Grunwald T; Foley P; Uberla K
    Hum Gene Ther; 2000 Nov; 11(17):2403-13. PubMed ID: 11096444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol.
    Lu X; Humeau L; Slepushkin V; Binder G; Yu Q; Slepushkina T; Chen Z; Merling R; Davis B; Chang YN; Dropulic B
    J Gene Med; 2004 Sep; 6(9):963-73. PubMed ID: 15352069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.
    Mautino MR; Keiser N; Morgan RA
    J Virol; 2001 Apr; 75(8):3590-9. PubMed ID: 11264348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors.
    Curran MA; Kaiser SM; Achacoso PL; Nolan GP
    Mol Ther; 2000 Jan; 1(1):31-8. PubMed ID: 10933909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multigene lentiviral vectors based on differential splicing and translational control.
    Zhu Y; Feuer G; Day SL; Wrzesinski S; Planelles V
    Mol Ther; 2001 Oct; 4(4):375-82. PubMed ID: 11592842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lentiviral vector delivery of recombinant small interfering RNA expression cassettes.
    Li MJ; Rossi JJ
    Methods Enzymol; 2005; 392():218-26. PubMed ID: 15644184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense.
    Mautino MR; Morgan RA
    Gene Ther; 2002 Apr; 9(7):421-31. PubMed ID: 11938457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A stable system for the high-titer production of multiply attenuated lentiviral vectors.
    Klages N; Zufferey R; Trono D
    Mol Ther; 2000 Aug; 2(2):170-6. PubMed ID: 10947945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defective lentiviral vectors are efficiently trafficked by HIV-1 and inhibit its replication.
    Klimatcheva E; Planelles V; Day SL; Fulreader F; Renda MJ; Rosenblatt J
    Mol Ther; 2001 Jun; 3(6):928-39. PubMed ID: 11407907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins.
    Pacchia AL; Adelson ME; Kaul M; Ron Y; Dougherty JP
    Virology; 2001 Mar; 282(1):77-86. PubMed ID: 11259192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing mobilization of simian immunodeficiency virus based vectors by primer complementation.
    Grunwald T; Pedersen FS; Wagner R; Uberla K
    J Gene Med; 2004 Feb; 6(2):147-54. PubMed ID: 14978768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Helper plasmids for production of HIV-1-derived vectors.
    Fuller M; Anson DS
    Hum Gene Ther; 2001 Nov; 12(17):2081-93. PubMed ID: 11747598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-inactivating lentiviral vectors with U3 and U5 modifications.
    Iwakuma T; Cui Y; Chang LJ
    Virology; 1999 Aug; 261(1):120-32. PubMed ID: 10441560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.